Advancing Immunology Clinical Development

Immunology studies can involve very different patient populations, therapeutic approaches, and regulatory requirements depending on the indication. Programs may also span biologics, biosimilars, antibodies, biomarker-driven development, precision medicine, and emerging immunotherapies.

  • Regulatory and Development Support

    • Global regulatory expertise for strategy and submissions
    • Support from early development through approval
    • Integrated operational and regulatory support across major global markets
  • Support for Complex Immunology Programs

    • Flexible delivery to meet program needs
    • Support across diverse immunology indications
    • Biologics, biosimilars, monoclonal and bispecific antibodies, and emerging immunotherapies
    • Biomarker-driven development, precision medicine, and complex endpoint strategies
  • Global Clinical Development Experience

    • Access to experienced immunology investigators, specialist sites, and patient populations
    • From first-in-human studies through registration-enabling programs
    • Regional expertise in key immunology research markets
  • Early Development
    Through Approval

  • Global Regulatory &
    Operational Support

  • Therapies Reaching
    Patients

  • Quality & Compliance
    at Every Step

  • Scientific Excellence
    & Innovation

  • Data Integrity &
    Transparency

Immunology Experience at a Glance

  • 519

    Immunology studies conducted

  • 1259

    Immunology investigators and key opinion leaders engaged

  • 1364

    Immunology sites activated globally

  • 41

    Countries supporting Immunology programs

  • 5875

    Immunology patients enrolled

  • 84

    Immunology indications supported

Breadth of Immunology Experience

Our experience spans a broad range of immunology indications, study designs, therapeutic approaches, and research settings.

Indication Experience

  • Experience across autoimmune, inflammatory, dermatologic, rheumatologic, and rare immune-mediated diseases

Study and Therapeutic Experience

  • Experience supporting complex study designs, biomarker-driven programs, and precision medicine approaches
  • Experience across small molecules, antibodies, immunotherapies, RNA, cell and gene therapies

Research Networks and Market Access

  • Established relationships with investigators, specialist treatment centers, and clinical research networks
  • Access to diverse patient populations across established and emerging research markets

Immunology Indications

Hover over each indication to explore conditions studied

 
  • Blood Diseases Alloimmune Thrombocytopenia; Autoimmune Haemolytic Anaemia, Cold Type; Autoimmune Haemolytic Anaemia, Warm Type; Immune Thrombocytopenic Purpura; Thrombotic Microangiopathy

  • Skin Diseases Alopecia; Alopecia Areata; Atopic Eczema; Dermatitis and Eczema; Generalised Pustular Psoriasis; Hidradenitis Suppurativa; Idiopathic angioedema; Palmoplantar Pustulosis; Pemphigus; Pemphigus foliaceus; Pemphigus Vulgaris; Plaque Psoriasis; Psoriasis; Pyoderma Gangrenosum; Vitiligo

  • Respiratory System Allergic Asthma; Allergic Rhinitis; Allergic Rhinitis due to House Dust Mite; Asthma; Chronic Rhinosinusitis; Vasomotor or Allergic Rhinitis

  • Visual System Optic Neuritis

  • Musculoskeletal System Axial Spondyloarthritis; Inflammatory Inclusion Body Myositis; Osteomyelitis or Osteitis; Psoriatic arthritis; Rheumatoid arthritis

  • Injury Failure or Rejection of Transplanted Organ

  • Digestive System Coeliac Disease; Crohn Disease; Inflammatory Bowel Diseases; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis; Ulcerative Colitis

  • Genitourinary System Glomerular Diseases

  • Health Status Factor Transplanted Kidney; Transplanted Lung; Transplanted Stem Cell

  • Immune System Acquired Angioedema; Allergy; Anaphylaxis; Autoinflammatory Disorders; Defects in the Complement System; Dermatomyositis; Graft-Versus-Host Disease; Hereditary Angioedema; Idiopathic Inflammatory Myopathy; Immune System Disorders; Immunodeficiencies with Antibody Defects; Lupus Erythematosus; Severe Combined Immunodeficiencies; Sjogren Syndrome; Systemic Autoimmune Disorders; Systemic Lupus Erythematosus; Systemic Sclerosis; Vasculitis

  • Nervous System Chronic Inflammatory Demyelinating Polyneuropathy; Congenital Myasthenia Syndrome; Guillain Barre Syndrome; Multiple Sclerosis; Myasthenia Gravis; Neuromyelitis Optica Spectrum

Therapeutic Approaches in Immunology

  • Biologics & Antibody-Based Therapies

    • Monoclonal Antibodies
    • Bispecific Antibodies
    • Cytokine-Targeted Therapies
    • Biosimilars
  • Precision & Targeted Immunology

    • Biomarker-Driven Therapies
    • Precision Medicine Approaches
    • Targeted Immune Modulation
    • Personalized Treatment Strategies
  • Advanced Therapeutic Approaches

    • Cell Therapies
    • Gene Therapies
    • RNA-Based Therapeutics
    • Next-Generation Immunotherapies

Expertise That Guides Infectious Disease Development

Our infectious disease leadership brings extensive therapeutic, clinical, and operational experience to help sponsors make informed development decisions and successfully execute trials across regions.